Validation of Cefiderocol Package Insert Dosing Recommendation for Patients Receiving Continuous Renal Replacement Therapy: A Prospective Multicenter Pharmacokinetic Study
The current package insert dosing recommendations resulted in pharmacodynamically optimized cefiderocol exposures. Cefiderocol concentrations exceeded relevant MIC breakpoints in all patients at each effluent flow rate, and AUC<sub>daily</sub> was within the range observed in patients in the phase 3 clinical trials, suggestive of a safe and therapeutic drug profile.
Authors
- Aliaa Fouad (ORCID: https://orcid.org/0009-0007-6467-1806)
- Emir Kobic (ORCID: https://orcid.org/0000-0001-9695-1836)
- Melissa L. Thompson Bastin (ORCID: https://orcid.org/0000-0001-8047-5978)
- Andrew J Fratoni (ORCID: https://orcid.org/0000-0002-5874-5174)
- Xiaoyi Ye (ORCID: https://orcid.org/0000-0001-5685-7239)
- Nelson Nicolasora
- Tomefa E. Asempa (ORCID: https://orcid.org/0000-0002-6268-0924)
- Joseph L. Kuti (ORCID: https://orcid.org/0000-0002-4464-3126)
- David P. Nicolau (ORCID: https://orcid.org/0000-0002-4148-0165)
- Paul Adams
- Yuwei Shen (ORCID: https://orcid.org/0009-0003-2542-386X)
Institutions
- Hartford Hospital (US)
- University of Kentucky (US)
- Banner - University Medical Center Phoenix (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1093/ofid/ofae451
- Citations
- 9
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- Shionogi